These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

133 related items for PubMed ID: 17438403

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. Effect of Carvedilol on Serum Heart-type Fatty Acid-binding Protein, Brain Natriuretic Peptide, and Cardiac Function in Patients With Chronic Heart Failure.
    Sun YP, Wei CP, Ma SC, Zhang YF, Qiao LY, Li DH, Shan RB.
    J Cardiovasc Pharmacol; 2015 May; 65(5):480-4. PubMed ID: 25945865
    [Abstract] [Full Text] [Related]

  • 3. Effects of carvedilol on plasma B-type natriuretic peptide concentration and symptoms in patients with heart failure and preserved ejection fraction.
    Takeda Y, Fukutomi T, Suzuki S, Yamamoto K, Ogata M, Kondo H, Sugiura M, Shigeyama J, Itoh M.
    Am J Cardiol; 2004 Aug 15; 94(4):448-53. PubMed ID: 15325927
    [Abstract] [Full Text] [Related]

  • 4. N-terminal prohormone brain natriuretic peptide plasma levels in heart failure are affected both directly and indirectly by carvedilol.
    Kallistratos MS, Dritsas A, Laoutaris ID, Cokkinos DV.
    Angiology; 2008 Aug 15; 59(3):323-8. PubMed ID: 18388105
    [Abstract] [Full Text] [Related]

  • 5. Impact of initiating carvedilol before angiotensin-converting enzyme inhibitor therapy on cardiac function in newly diagnosed heart failure.
    Sliwa K, Norton GR, Kone N, Candy G, Kachope J, Woodiwiss AJ, Libhaber C, Sareli P, Essop R.
    J Am Coll Cardiol; 2004 Nov 02; 44(9):1825-30. PubMed ID: 15519014
    [Abstract] [Full Text] [Related]

  • 6. Serum biomarkers and clinical outcomes in heart failure patients treated de novo with carvedilol.
    Nessler J, Nessler B, Golebiowska-Wiatrak R, Palka I, Gackowski A, Kitlinski M, Melander O, Fedorowski A.
    Cardiol J; 2013 Nov 02; 20(2):144-51. PubMed ID: 23558872
    [Abstract] [Full Text] [Related]

  • 7. Concentration of BNP, endothelin 1, pro-inflammatory cytokines (TNF-alpha, IL-6) and exercise capacity in patients with heart failure treated with carvedilol.
    Nessler J, Nessler B, Kitliński M, Gackowski A, Piwowarska W, Stepniewski M.
    Kardiol Pol; 2008 Feb 02; 66(2):144-51; discussion 152-3. PubMed ID: 18344152
    [Abstract] [Full Text] [Related]

  • 8. Increased low-grade inflammation is associated with lack of functional response to carvedilol in patients with systolic heart failure.
    Fragasso G, Spoladore R, Maranta F, Corti A, Lattuada G, Colombo B, Locatelli M, Salerno A, Calori G, Briceno L, Alfieri AB, Perseghin G, Margonato A.
    J Cardiovasc Med (Hagerstown); 2013 Jan 02; 14(1):49-56. PubMed ID: 23018486
    [Abstract] [Full Text] [Related]

  • 9. Differences between beta-blockers in patients with chronic heart failure and chronic obstructive pulmonary disease: a randomized crossover trial.
    Jabbour A, Macdonald PS, Keogh AM, Kotlyar E, Mellemkjaer S, Coleman CF, Elsik M, Krum H, Hayward CS.
    J Am Coll Cardiol; 2010 Apr 27; 55(17):1780-7. PubMed ID: 20413026
    [Abstract] [Full Text] [Related]

  • 10. Prognostic importance of plasma NT-pro BNP in chronic heart failure in patients treated with a beta-blocker: results from the Carvedilol Or Metoprolol European Trial (COMET) trial.
    Olsson LG, Swedberg K, Cleland JG, Spark PA, Komajda M, Metra M, Torp-Pedersen C, Remme WJ, Scherhag A, Poole-Wilson P, COMET Investigators.
    Eur J Heart Fail; 2007 Aug 27; 9(8):795-801. PubMed ID: 17693380
    [Abstract] [Full Text] [Related]

  • 11. Carvedilol therapy is associated with a sustained decline in brain natriuretic peptide levels in patients with congestive heart failure.
    Frantz RP, Olson LJ, Grill D, Moualla SK, Nelson SM, Nobrega TP, Hanna RD, Backes RJ, Mookadam F, Heublein D, Bailey KR, Burnett JC.
    Am Heart J; 2005 Mar 27; 149(3):541-7. PubMed ID: 15864245
    [Abstract] [Full Text] [Related]

  • 12. Restrictive left ventricular filling pattern and its effect on the clinical course of systolic heart failure in patients receiving carvedilol.
    Nessler J, Nessler B, Kitliński M, Stepniewski M, Piwowarska W.
    Cardiol J; 2008 Mar 27; 15(4):329-37. PubMed ID: 18698541
    [Abstract] [Full Text] [Related]

  • 13. Low-dose carvedilol improves left ventricular function and reduces cardiovascular hospitalization in Japanese patients with chronic heart failure: the Multicenter Carvedilol Heart Failure Dose Assessment (MUCHA) trial.
    Hori M, Sasayama S, Kitabatake A, Toyo-oka T, Handa S, Yokoyama M, Matsuzaki M, Takeshita A, Origasa H, Matsui K, Hosoda S, MUCHA Investigators.
    Am Heart J; 2004 Feb 27; 147(2):324-30. PubMed ID: 14760332
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. [Preliminary study on the effect of carvedilol on children with primary endocardial fibroelastosis].
    Li R, Yi QJ, Qian YR, Liu XY, Zhong JR, Bai YH, Mi Q, Li XL.
    Zhonghua Er Ke Za Zhi; 2008 Sep 27; 46(9):684-7. PubMed ID: 19099859
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. The effect of carvedilol on B-type natriuretic peptide and cardiac function in patients with heart failure and persistent atrial fibrillation.
    Khand AU, Chew PG, Douglas H, Jones J, Jan A, Cleland JG.
    Cardiology; 2015 Sep 27; 130(3):153-8. PubMed ID: 25660493
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 7.